PO.SHP01.01 · 科学与健康政策

Artemis项目:一个以患者为主导、推进以预防为核心的乳腺癌创新的全球研究联合体

The Artemis Project: A patient-led global research consortium advancing prevention-focused breast cancer innovation

海报缩略图:Artemis项目:一个以患者为主导、推进以预防为核心的乳腺癌创新的全球研究联合体
编号 3695 展板 22 时间 4/20 02:00–05:00 区域 Section 39 主讲 Michelle Tregear, PhD
分会场 Science and Health Policy 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Fran M. Visco1, Jayanta Debnath2, Daniel Douek3, Stephen J. Elledge4, Silvia C. Formenti5, Michele S. Garfinkel1, Cyrus M. Ghajar6, Patricia K. Haugen7, Christopher I. Li6, Herbert Kim Lyerly8, Michelle Tregear1, Alana L. Welm9, Frank J. Calzone10

1National Breast Cancer Coalition, Washington, DC,2UCSF - University of California San Francisco, San Francisco, CA,3Human Immunology Section, NIAID, NIH, Bethesda, MD,4Harvard Medical School, Boston, MA,5Weill Cornell Medicine, New York, NY,6Fred Hutchinson Cancer Research Center, Seattle, WA,7Independent advocate, Sioux Falls, SD,8Professor, Duke University (Columbus, OH), Durham, NC,9University of Utah Huntsman Cancer Institute, Salt Lake City, UT,10Self-employed consultant, Westlake Village, CA

摘要 Abstract

中文摘要
目的:成立于1991年的美国全国乳腺癌联盟(NBCC)是活动人士、幸存者、基层团体和全国性组织的协作体,团结一致通过行动和倡导来终结乳腺癌。尽管在某些领域取得了进展,但乳腺癌的发病率和全球死亡率均未显著下降。为应对这一状况,NBCC于2010年启动了Artemis项目,这是一项由倡导者主导的倡议,聚焦于乳腺癌的一级预防和转移的预防,旨在促进研究者与倡导者之间的新协作。该项目是对以下事实的回应:尽管投入了数十亿美元的研究并催生了一些有效的治疗,我们仍不知道如何预防或治愈乳腺癌。 Artemis流程:Artemis项目是一项旨在识别紧迫缺口、设定里程碑并共同开发针对一级预防和转移预防的研究解决方案的协作。与传统的研究开发流程不同,Artemis将受过训练的患者倡导者作为平等的合作伙伴纳入优先事项设定、研究设计和监督之中。倡导者确定参与者并选择议题。协作在年度会议上形成,参与其中的研究者和倡导者往往在其他情况下本不会相遇。一年一度的Artemis会议将参与者聚集在一起,探索新思路,为实现Artemis的目标开发创新项目,并勾勒会后12-18个月的工作计划。全年举行线上会议,供各团队互动并汇报进展。部分项目的种子资金由NBCC提供。NBCC全年为Artemis参与者就相关主题安排网络研讨会。 部分Artemis成果:首个Artemis项目催生了一项正在进行的开发乳腺癌预防疫苗的倡议,并已制定计划于2026年年中进入I期试验。该疫苗由6种在乳腺癌中过表达的自身抗原组成,正在NCI Prevent计划的合同下开发。源自另一个Artemis项目的DNA Land已招募超过33,000名个体,他们已同意并贡献了基因组数据及匹配的表型数据,以支撑用于以预防为核心的乳腺癌研究的生物信息学研究。此外,参与Artemis的研究者已建立了众多协作,这些协作已发展成为获得外部资助的研究工作,包括一个旨在清除播散性肿瘤细胞的项目。 结论:如今已进入第15个年头,Artemis项目已创建了一个持久的、由倡导者主导的生态系统,将研究者、临床医生和倡导者团结起来,追求变革性的预防解决方案,而非渐进式的进展。这一模式可在各疾病研究领域推广应用。
查看英文原文 English abstract
Purpose: The National Breast Cancer Coalition (NBCC), established in 1991, is a collaboration of activists, survivors, grassroots groups and national organizations united to end breast cancer through action and advocacy. Despite progress in certain areas, neither breast cancer incidence nor global mortality have significantly declined. In response, NBCC launched the Artemis Project in 2010, an advocate-led initiative focused on primary prevention of breast cancer and prevention of metastasis, designed to foster new collaborations among researchers and advocates. The project is a response to the fact that despite billions of dollars invested in research that has led to some effective treatments, we still do not know how to prevent or cure breast cancer. Artemis process: The Artemis Project is a collaboration to identify urgent gaps, set milestones, and co-develop research solutions to primary and metastasis prevention. Unlike traditional research development pipelines, Artemis integrates trained patient advocates as equal partners in priority setting, research design and oversight. Advocates identify the participants and choose the issues. Collaborations form at the annual meeting among researchers and advocates who often would not have met otherwise.The annual Artemis meeting brings participants together to explore new ideas, develop innovative projects towards Artemis's goals, and outline work plans for 12-18 months after the meeting. Online meetings are held throughout the year for the groups to interact and to report progress. Seed funding for some projects has been provided by NBCC. NBCC schedules webinars throughout the year on relevant topics for Artemis participants. Selected Artemis outcomes: The first Artemis project led to an ongoing initiative to develop a breast cancer prevention vaccine, with a plan in place to move to a Phase I trial by mid-2026. The vaccine, consisting of 6 self-antigens overexpressed in breast cancer, is being developed under a contract with the NCI Prevent Program. DNA Land, an effort stemming from another Artemis project, has recruited over 33,000 individuals who have consented and contributed genomic and matched phenotypic data to underpin bioinformatics studies supporting prevention-focused breast cancer research.Additionally, researchers participating in Artemis have formed many collaborations that have grown into externally funded research efforts, including a project to eliminate disseminated tumor cells. Conclusions: Now 15 years in, the Artemis Project has created a durable, advocate-led ecosystem that unites researchers, clinicians, and advocates to pursue transformative prevention solutions rather than incremental advances. This model is adaptable across disease research areas.
利益披露 Disclosure
F. M. Visco, None.. D. Douek, None.. M. S. Garfinkel, None.. P. K. Haugen, None.. M. Tregear, None.. F. J. Calzone, None.

← 返回 AACR 2026 检索